SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts Foci of iron deposition in the perinuclear mitochondria of erythroid precursors, called ring sideroblasts (RS), can be seen in acquired and congenital cases of anemia. In many patients with myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and myelodysplastic syndrome (MDS), various frequencies of RS can be found when stained with Prussian blue. 1 The finding of 415% RS together with the appropriate morphologic and cytogenetic criteria is consistent with the diagnosis of refractory anemia with RS (RARS). 2 RS can be also found in a form of MDS/MPN called refractory anemia with RS associated with marked thrombocytosis (RARS-T). Patients with RARS and RARS-T were also found to have mutations in JAK2, MPL, TET2 and ASXL1. [3] [4] [5] [6] [7] [8] However, the clinical relevance and etiology of RS in MDS and MDS/MPN remain unclear due to the lack of specific molecular defects, including recurrent chromosomal abnormalities or mutations. High throughput-next generation sequencing (HT-NGS) is being widely used to identify mutational events in leukemia and other cancers. 9 We applied this technology to patients with various forms of MDS; using this approach, we found a somatic mutation in SF3B1, a gene located in chromosome 2q in a patient with RARS and high platelet counts. SF3B1, splicing factor 3b, subunit 1, is a component of the U2-small nuclear ribonucleoprotein (U2-snRNP) complex. U2-snRNP complex is one of the two unique spliceosomes present in eukaryotic cells. It consists of SF3b, SF3a and U2-snRNP-specific proteins. 10 Approximately 95% of messenger RNAs (mRNAs) have intronic regions that require further modification by spliceosomes to produce normal mRNAs. Aberrant splicing and mutations of these splicing mechanisms have been described in cancer. [11] [12] The current study describes recurrent mutations of a novel gene, SF3B1 in RARS. Study samples from 14 patients with RARS, 18 patients with RARS-T and 24 patients with similar morphologic features but without RS were analyzed. We applied the HT-NGS technology to interrogate the genome of a group of 11 MDS patients with various pathomorphologic features including patients with RARS-T, CMML-1, RAEB-1/2, RCMD and AML. In a patient with RARS-T, we found a possible candidate gene, SF3B1, an integral member of the spliceosome complex (patient no. 13; Table 1 and Figure 2b) . A specific missense mutation at amino-acid position 700 was detected, which resulted in the substitution of glutamic acid for lysine (K700E) (Figure 1a) . The somatic nature of this mutation was confirmed by sequencing non-clonal CD3 þ cells by Sanger method (Figure 1b) . Analysis of the other 10 patients studied by HT-NGS did not reveal any clonal SF3B1 sequence alterations. None of these patients showed RS except one with o15% RS. Based on this finding, we decided to focus on a larger cohort of patients with RARS. We found that 9/14 (64%) patients with RARS and 13/18 (72%) patients with RARS-T have mutations in SF3B1 (Figure 2a ). Clinical and molecular features of mutant cases are summarized in Table 1 . Of note is that, SF3B1 mutations were all heterozygous, and 50% of patients with RARS and 44% of patients with RARS-T harbor a common missense mutation, K700E, already reported in pancreatic tumor cells (http://www.sanger.ac.uk), and detected by the HT-NGS in the index case (patient no. 13, Table 1 ). All other mutations were novel, and the somatic nature was confirmed in non-clonal CD3 þ cells (Figure 1c ). Two mutations (R625L, patient no. 12 and R625C, patient no. 15) ( Table 1) could not be confirmed due to a lack of germline DNA, but they were absent in normal controls and in SNP databases. We also screened SF3B1 in a heterogeneous group of 24 patients with MDS and MPN without RS, and o15% RS finding no mutation in SF3B1 (Figure 2a ). Affymetrix 6.0 array-based cytogenetics was used in 430 patients with MDS to detect the presence of deletions and uniparental dysomy involving SF3B1 locus. Detection algorithm indicated a possible loss of heterozygosity in a large region of chromosome 2q in two non-MDS patients without RS, but bidirectional sequencing did not reveal any mutations in any of the exons of SF3B1. When we sequenced a patient with congenital sideroblastic anemia with numerous RS and platelet count of 541 Â 10 9 /L, we did not find any mutations in any of the exons. Of note, we also identified a patient with postpolycythemic myelofibrosis with occasional RS, platelet count of 727 Â 10 9 /L and JAK2 negative, which was mutated (K700E). Altogether these observations lead us to speculate that SF3B1 is highly specific in RARS pathogenesis.
We next noticed that patients harboring SF3B1 mutations are mainly RARS with normal and elevated platelet counts. We found a statistically significantly higher frequency of arterial and venous thrombotic events in patients who carry SF3B1 mutations. For 15 patients with complete clinical information regarding thrombotic events, 6 out of 10 patients with mutations had thrombotic events (P ¼ 0.04). None of the four wild-type patients studied had any thrombotic events. A majority of the patients are still alive with no statistically significant difference in median survival between mutant carriers and wild-type cases, a fact not surprising due to good overall prognosis of patients with RARS.
We also observed that in RARS-T, SF3B1 was associated with JAK2 V617F (4/13; 30%), MPL (3/13; 23%) and pSTAT5 (7/11; 64%). One RARS-T patient (no. 1) showed a missense mutation in LNK exon 2 (a substitution of an isoleucine for a serine, S186I, 557 G4A) occurring concurrently with JAK2 V617F and SF3B1 in this patient. 13 DNMT3A has already been associated with patients with RARS, 14 and we also found DNMT3A mutations in 3/18 (17%) patients with RARS-T and 6/14 (42%) patients with RARS; 4/6 had concomitant SF3B1 mutations (data not shown). One patient with RARS (patient no. 17) showed a missense mutation in IDH1 (R132C, 394 C4T) with no other concurrent mutations (data not shown). The constellation of all the mutations found in this cohort is illustrated in Figure 2b . Given the low incidence of mutational events in JAK2 and MPL in patients with RARS, we cannot correlate these mutations with SF3B1 in this group of patients.
Gene expression is a complex process that requires the excision of intronic regions from pre-mRNA through a sophisticated spliceosome component, U2-snRNP.
10 SF3B1 (also called SAP155) is located at the U2-snRNP spliceosome catalytic site, and has an important role in the prespliceosome assembly and splicing catalysis. It has been reported that SF3B1 is the only component to be phosphorylated in functional spliceosomes. Alteration of the splicing process can lead to aberrant protein products and this may be of clinical relevance in other human diseases. 11 Our findings of mutations in proteins involved in RNA splicing open a new road of investigation in the pathogenesis of RARS. Although there is extensive evidence implicating abnormal expression of genes involved in heme biosynthesis, iron processing and altered mitochondrial function in the pathogenesis of RARS, none have been translated to targeted and improved therapies for these diseases. 15, 16 It is possible that the role of the spliceosome in RARS and related diseases is not restricted to SF3B1, and may involve other components of the splicing machinery. This prompted us to also perform genomic sequencing of two other spliceosome components associated with SF3B1: SF3B14 and SF3B4. In addition, SNP-A karyotyping identified uniparental dysomy /l). c Patient #8 received hydroxyurea. Gray color highlights the index case: the patient on which high-throughput next generation sequencing was performed.
Letters to the Editor in two patients with RARS-T (patient no. 11 and patient no. 15, Figure 2b ) in the region of SF3B14. However, no SF3B14 mutations were found in both patients. Similarly, no mutation was found in another splicing factor, subunit b, SF3B4. Investigations of other components of the spliceosome machinery are underway, including proximal components of the splicing factors, subunit b and eventually the target proteins.
We conclude that patients with RARS have unique defects in the spliceosome machinery that can cause altered pre-mRNA splicing and ultimately lead to the classical phenotype of RS observed in these patients. SF3B1 may be a potential novel Table 1 ). Black lines and arrows indicate the nucleotide triplets and substitution. Forward and reverse sequencing is presented also for non-clonal CD3 positive lymphocytes isolated from the same patient showing that the nucleotide change observed in the BM is only barely visible in lymphocytes and confirming the somatic nature of the mutation. (c) Schematic representation of the topographic distribution of SF3B1 (NM_012433) mutations is represented for 13 patients with RARS-T (upper part) and 9 patients with RARS (lower part). Each patient is represented with a circle. Six missense mutations and three missense mutations and one deletion located proximal to exon 14 and exon 15 of SF3B1 (600-700 bp) are shown for patients with RARS-T and RARS, respectively. Light blue and red colors indicate missense mutations and deletion, respectively. Mutations were confirmed to be somatic. A, adenine; C, cysteine; C, cytosine; CTD SF3B1, comparative toxigenomics database for SF3B1; D, aspartic acid; E, glutamic acid; G, guanine; H, histidine; HSH155, alternative name of SF3B1; K, lysine; L, leucine; M, methionine; Q, glutamine; R, arginine; SF3B1, splicing factor 3b, subunit 1 isoform 1; T, threonine; T, thymidine.
Letters to the Editor marker in the diagnosis of RARS and in the prediction of thrombotic events in patients with RARS-T.
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